PSTX Stock Price, Poseida Therapeutics, . Quote, Chart

Market Summary

USD3.49+0.03

Delayedas of 16 May 2024, 10:45 am

0.87%

PSTX Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)
Losses in recent quarter

PSTX Stock Price

View Fullscreen

PSTX RSI Chart

PSTX Valuation

Market Cap

335.5M

Price/Earnings (Trailing)

-3.08

Price/Sales (Trailing)

4.07

EV/EBITDA

-70.83

Price/Free Cashflow

-4.68

PSTX Price/Sales (Trailing)

PSTX Profitability

EBT Margin

-23.50%

Return on Equity

-128.68%

Return on Assets

-41.46%

Free Cashflow Yield

-21.38%

PSTX Fundamentals

PSTX Revenue

Revenue (TTM)

82.5M

Rev. Growth (Yr)

172.09%

Rev. Growth (Qtr)

12.59%

PSTX Earnings

Earnings (TTM)

-108.9M

Earnings Growth (Yr)

37.51%

Earnings Growth (Qtr)

4.24%

Breaking Down PSTX Revenue

52 Week Range

1.543.55

(Low)(High)

Last 7 days

27.3%

Last 30 days

42.0%

Last 90 days

-6.8%

Trailing 12 Months

19.0%

How does PSTX drawdown profile look like?

PSTX Financial Health

Current Ratio

2.56

Debt/Equity

0.69

Debt/Cashflow

-1.18

PSTX Investor Care

Shares Dilution (1Y)

11.73%

Diluted EPS (TTM)

-1.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	82.5M	0	0	0
2023	139.4M	156.7M	49.8M	64.7M
2022	56.1M	80.9M	105.7M	130.5M
2021	0	0	0	31.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Poseida Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	rizvi syed ali-aamir	acquired	-	-	185,000	chief medical officer
Mar 01, 2024	mylet johanna	sold (taxes)	-74,715	4.13	-18,091	chief financial officer
Mar 01, 2024	warner brent	acquired	-	-	80,743	president, gene therapy
Mar 01, 2024	warner brent	sold (taxes)	-147,602	4.13	-35,739	president, gene therapy
Mar 01, 2024	mylet johanna	acquired	-	-	80,743	chief financial officer
Mar 01, 2024	gergen mark j	sold (taxes)	-141,068	4.13	-34,157	executive chairman
Mar 01, 2024	leonhardt harry j	acquired	-	-	80,743	gc & chief compliance officer
Mar 01, 2024	leonhardt harry j	sold (taxes)	-67,343	4.13	-16,306	gc & chief compliance officer
Feb 01, 2024	gergen mark j	sold (taxes)	-160,822	3.41	-47,162	executive chairman
Jan 02, 2024	gergen mark j	acquired	-	-	125,000	executive chairman

Which funds bought or sold PSTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Cubist Systematic Strategies, LLC	sold off	-100	-55,423	-	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	reduced	-54.07	-44,790	34,640	-%
May 15, 2024	Point72 Asset Management, L.P.	sold off	-100	-1,125,600	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	205,512	205,512	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-4.34	-145,316	1,437,150	-%
May 15, 2024	Royal Bank of Canada	reduced	-87.94	-70,000	9,000	-%
May 15, 2024	Boxer Capital, LLC	new	-	14,275,200	14,275,200	0.70%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-37.34	-14,538	21,344	-%
May 15, 2024	Pentwater Capital Management LP	unchanged	-	-1,015,750	19,060,200	0.20%
May 15, 2024	CANTOR FITZGERALD, L. P.	added	49.8	71,215	239,904	0.06%

Are Funds Buying or Selling PSTX?

Are funds buying PSTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PSTX

No. of Funds

Unveiling Poseida Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 08, 2024	novartis pharma ag	12.%	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 31, 2024	blackrock inc.	5.3%	5,031,173	SC 13G
Aug 14, 2023	astellas us llc	8.7%	-	SC 13D
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Apr 25, 2022	pentwater capital management lp	7.94%	4,967,227	SC 13D/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 12, 2021	novartis pharma ag	9.6%	5,908,089	SC 13G
Feb 08, 2021	fmr llc	-	0	SC 13G/A
Feb 03, 2021	malin life sciences holdings ltd	14.9%	9,188,125	SC 13G

Recent SEC filings of Poseida Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 08, 2024	SC 13G/A	Major Ownership Report
May 03, 2024	EFFECT	EFFECT
May 01, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 17, 2024	8-K	Current Report
Apr 08, 2024	S-3	S-3

Peers (Alternatives to Poseida Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.5B	6.8B	24.29%	3.18%	-8.29	7.22	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.16%	-22.78%	-56.17	9.31	75.20%	68.82%
BMRN	15.3B	2.5B	-12.17%	-12.66%	74.28	6.17	13.74%	186.89%
INCY	12.8B	3.8B	6.79%	-11.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	16.38%	112.85%	-10.26	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.64%	-52.21%	-12.19	9.71	394.93%	39.61%
AXSM	3.6B	251.0M	11.42%	-1.40%	-12.17	14.37	73.58%	-86.73%
ARWR	3.1B	240.7M	4.29%	-33.48%	-6.61	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-10.48%	-30.90%	-1.5K	3.07	56.43%	98.83%
SMALL-CAP
CPRX	2.0B	411.3M	8.25%	33.17%	30.22	4.78	60.38%	-34.49%
NVAX	1.8B	996.6M	212.62%	68.59%	-4.54	1.81	-26.66%	65.49%
CRBP	472.0M	881.7K	3.39%	323.08%	-13.98	481.06	-77.61%	33.36%
INO	339.4M	4.9M	19.20%	55.95%	-2.72	69.75	-54.97%	48.23%
IBIO	16.2M	2.1M	-2.59%	102.15%	-0.7	7.61	-13.45%	69.54%

Poseida Therapeutics, Inc. News

Latest updates

Poseida Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	12.6%	28,142,000	24,995,000	9,352,000	20,013,000	10,343,000	10,051,000	116,306,000	2,700,000	1,435,000	-
Operating Expenses	3.6%	52,719,000	50,905,000	45,574,000	47,868,000	49,859,000	43,271,500	44,526,000	44,245,000	58,396,000	48,716,000
S&GA Expenses	-100.0%	-	8,859,500	8,092,000	8,676,000	11,807,000	9,367,500	9,389,000	9,237,000	9,546,000	9,609,000
R&D Expenses	2.1%	42,921,000	42,045,500	37,482,000	39,192,000	38,052,000	33,904,000	35,137,000	35,008,000	48,850,000	39,107,000
EBITDA Margin	26.5%	-0.06	-0.08	-0.44	-0.31	-0.38	-0.41	-0.21	-1.68	-2.43	-3.75
Interest Expenses	-0.6%	2,253,000	2,266,500	2,236,000	2,141,000	2,028,000	3,518,000	1,775,000	-1,543,000	1,077,000	840,000
Income Taxes	-	-	-	107,000	-	-	292,000	252,000	-	-	-
Earnings Before Taxes	100.0%	-	-25,349,000	-31,671,000	-	-	-33,026,000	70,661,000	-43,036,000	-58,057,000	1,469,000
EBT Margin	21.6%	-0.23	-0.30	-0.75	-0.40	-0.46	-0.49	-0.27	-1.76	-2.58	-4.00
Net Income	4.2%	-24,274,000	-25,349,000	-31,778,000	-27,456,000	-38,847,000	-33,318,000	70,409,000	-43,036,000	-58,057,000	1,443,000
Net Income Margin	30.8%	-1.32	-1.91	-2.64	-0.19	-0.32	-0.49	-0.28	-1.76	-2.58	-4.00
Free Cashflow	47.5%	-15,265,000	-29,053,000	7,099,000	-34,490,000	-38,789,000	2,143,000	60,175,000	-40,947,000	-52,067,000	8,260,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-4.1%	263	274	302	281	314	352	380	205	248	269	262	299	333	371	405	226	147
Current Assets	-4.3%	217	226	253	230	261	299	325	148	191	214	205	240	274	314	347	173	127
Cash Equivalents	19.8%	53.00	44.00	26.00	50.00	40.00	81.00	165	63.00	184	206	198	200	170	84.00	66.00	147	88.00
Net PPE	-3.6%	18.00	19.00	20.00	21.00	22.00	22.00	22.00	23.00	22.00	22.00	22.00	23.00	23.00	23.00	24.00	22.00	11.00
Goodwill	0%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	4.6%	178	170	179	146	156	164	164	140	144	113	112	113	106	110	109	105	74.00
Current Liabilities	18.9%	85.00	71.00	77.00	50.00	49.00	54.00	49.00	40.00	44.00	43.00	32.00	32.00	28.00	30.00	30.00	29.00	22.00
Long Term Debt	0.2%	59.00	59.00	58.00	58.00	58.00	58.00	58.00	58.00	58.00	29.00	29.00	29.00	26.00	29.00	29.00	29.00	26.00
LT Debt, Non Current	-100.0%	-	59.00	58.00	58.00	58.00	58.00	58.00	58.00	58.00	29.00	29.00	29.00	26.00	29.00	29.00	29.00	26.00
Shareholder's Equity	-18.4%	85.00	104	124	135	158	188	216	66.00	104	156	150	187	227	262	296	-	262
Retained Earnings	-4.1%	-618	-594	-568	-537	-509	-470	-437	-508	-464	-406	-408	-365	-320	-281	-245	-211	-152
Additional Paid-In Capital	0.8%	703	698	693	673	667	659	654	574	569	563	558	552	548	544	542	6.00	3.00
Shares Outstanding	1.2%	97.00	96.00	96.00	87.00	87.00	86.00	67.00	63.00	63.00	63.00	62.00	62.00	-	-	-	-	-
Float	-	-	-	-	123	-	-	-	100	-	-	-	357	-	-	-	516	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	47.3%	-15,135	-28,744	7,888	-33,306	-38,005	2,403	61,878	-39,729	-51,324	8,473	-40,872	-31,088	-39,056	-30,315	-29,327	-30,801	-22,885	-	-	-
Share Based Compensation	6.3%	5,383	5,063	5,117	5,474	7,480	4,548	4,277	5,234	4,867	4,349	4,151	4,742	3,462	2,200	1,895	1,616	1,509	-	-	-
Cashflow From Investing	-49.7%	24,003	47,713	-47,237	43,073	-4,415	-85,890	-35,872	-80,829	-743	-195	37,135	60,919	124,525	47,972	-258,064	11,634	-5,973	-	-	-
Cashflow From Financing	-Infinity%	-43.00	-	14,941	-	1,186	58.00	75,838	32.00	29,231	236	1,855	67.00	360	38.00	206,529	103,028	4,346	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PSTX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Collaboration revenue	$ 28,142	$ 10,343
Operating expenses:
Research and development	42,921	38,052
General and administrative	9,798	11,807
Total operating expenses	52,719	49,859
Loss from operations	(24,577)	(39,516)
Other income (expense):
Interest expense	(2,253)	(2,028)
Other income, net	2,556	2,697
Net loss	(24,274)	(38,847)
Other comprehensive income (expense):
Unrealized gain (loss) on short-term investments	(173)	151
Comprehensive loss	$ (24,447)	$ (38,696)
Net loss per share attributable to common stockholders, basic	$ (0.25)	$ (0.45)
Net loss per share attributable to common stockholders, diluted	$ (0.25)	$ (0.45)
Weighted-average number of shares outstanding, basic	96,019,579	86,265,223
Weighted-average number of shares outstanding, diluted	96,019,579	86,265,223
Collaboration Revenue
Revenues:
Collaboration revenue	$ 28,142	$ 10,343

PSTX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 53,297	$ 44,472
Short-term investments	145,349	167,730
Accounts receivable	12,027	9,010
Prepaid expenses and other current assets	6,059	5,263
Total current assets	216,732	226,475
Property and equipment, net	18,364	19,055
Operating lease right-of-use assets	20,855	21,726
Intangible assets, net	1,320	1,320
Goodwill	4,228	4,228
Other long-term assets	1,081	1,081
Total assets	262,580	273,885
Current liabilities:
Accounts payable	2,704	3,267
Accrued expenses and other liabilities	26,294	31,092
Operating lease liabilities, current	5,995	5,951
Deferred revenue, current	49,770	31,008
Total current liabilities	84,763	71,318
Term debt	58,691	58,590
Deferred revenue, noncurrent	11,903	16,780
Operating lease liabilities, non-current	19,875	20,882
Other long-term liabilities	2,754	2,614
Total liabilities	177,986	170,184
Commitments and Contingencies (Note 12)
Stockholders’ equity:
Common stock, $0.0001 par value: 250,000,000 shares authorized at March 31,2024 and December 31, 2023; 96,798,009 and 95,636,553 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	10	10
Additional paid-in capital	703,196	697,856
Accumulated other comprehensive income (loss)	(47)	126
Accumulated deficit	(618,565)	(594,291)
Total stockholders’ equity	84,594	103,701
Total liabilities and stockholders’ equity	$ 262,580	$ 273,885

About Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

CEO	Mr. Mark J. Gergen J.D.
WEBSITE	https://poseida.com
INDUSTRY	Biotechnology
EMPLOYEES	348

Poseida Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Poseida Therapeutics, Inc.? What does PSTX stand for in stocks?

PSTX is the stock ticker symbol of Poseida Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Poseida Therapeutics, Inc. (PSTX)?

As of Wed May 15 2024, market cap of Poseida Therapeutics, Inc. is 335.47 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PSTX stock?

You can check PSTX's fair value in chart for subscribers.

What is the fair value of PSTX stock?

You can check PSTX's fair value in chart for subscribers. The fair value of Poseida Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Poseida Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PSTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Poseida Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether PSTX is over valued or under valued. Whether Poseida Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Poseida Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PSTX.

What is Poseida Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 15 2024, PSTX's PE ratio (Price to Earnings) is -3.08 and Price to Sales (PS) ratio is 4.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSTX PE ratio will change depending on the future growth rate expectations of investors.